drugset
drugset / Trial / NCT00994500

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

NCT00994500 ↗

Phase 1 Completed 20 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating young patients with refractory or recurrent solid tumors, including CNS tumors and lymphoma. Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Timeline

Start
2009-08
Primary completion
2011-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — Intravenous
Subject Vorinostat Small molecule — Oral

Indications

Burkitt lymphoma Hodgkins lymphoma anaplastic large cell lymphoma central nervous system teratoma cerebellar astrocytoma childhood brain meningioma childhood brain stem glioma childhood central nervous system germinoma childhood central nervous system mixed germ cell tumor childhood cerebral astrocytoma childhood choroid plexus neoplasm childhood ependymoma childhood medulloblastoma childhood oligodendroglioma craniopharyngioma extranodal nasal NK/T cell lymphoma grade III lymphomatoid granulomatosis large-cell immunoblastic lymphoma medulloepithelioma mixed glioma optic pathway glioma pediatric CNS choriocarcinoma pineoblastoma precursor lymphoblastic lymphoma/leukemia subependymal giant cell astrocytoma supratentorial primitive neuroectodermal tumor yolk sac tumor of central nervous system